Key result
Bupivacaine reversibly inhibited small-conductance calcium-activated potassium type 2 (SK2) channels in a dose-dependent manner with an IC50 of 16.5 µM.
Why the study?
Bupivacaine blocks many cardiac ion channels causing cardiotoxicity, but whether it inhibits SK2 channels, which are widely distributed in heart cells, remains unclear.
Bupivacaine reversibly inhibits SK2 channels in a dose-dependent manner, providing a potential mechanism for its cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Bupivacaine SK2 inhibition is hypothesis-generating; leaves open in vivo relevance and any clinical implications.
BACKGROUND: Bupivacaine blocks many ion channels in the heart muscle, causing severe cardiotoxicity. Small-conductance calcium-activated potassium type 2 channels (SK2 channels) are widely distributed in the heart cells and are involved in relevant physiological functions. However, whether bupivacaine can inhibit SK2 channels is still unclear. This study investigated the effect of bupivacaine on SK2 channels. METHODS: The SK2 channel gene was transfected into human embryonic kidney 293 cells (HEK-293 cells) with Lipofectamine 2000. The whole-cell patch-clamp technique was used to examine the effect of bupivacaine on SK2 channels. The concentration-response relationship of bupivacaine for inhibiting SK2 currents (0 mV) was fitted to a Hill equation, and the half-maximal inhibitory concentration (IC50) value was determined. RESULTS: Bupivacaine inhibited the SK2 channels reversibly in a dose-dependent manner. The IC50 value of bupivacaine, ropivacaine, and lidocaine on SK2 currents was 16.5, 46.5, and 77.8µM, respectively. The degree of SK2 current inhibition by bupivacaine depended on the intracellular concentration of free calcium. CONCLUSIONS: The results of this study suggested the inhibitory effect of bupivacaine on SK2 channels. Future studies should explore the effects of SK2 on bupivacaine cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) studied Bupivacaine cardiotoxicity. Bupivacaine vs. Baseline (Tyrode's solution) was evaluated on Half-maximal inhibitory concentration (IC50) of bupivacaine on SK2 currents (IC50 16.5 µM, 95% CI 12.46-21.83). Bupivacaine reversibly inhibited small-conductance calcium-activated potassium type 2 (SK2) channels in a dose-dependent manner with an IC50 of 16.5 µM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: